Navigation

Type 2 diabetes - newer agents

Type 2 diabetes - newer agents for blood glucose control in type 2 diabetes

Status: History
Publication date: May 2009
Wave: 16
Process: SCG
Topic area:
  • Endocrine, nutritional and metabolic
 

NICE project team

Centre for clinical practice lead: Fergus Macbeth
Communications manager: Kristin O'Leary
Guidelines commissioning manager: Nicole Elliot
Guidelines coordinator: Emma Banks
Patient involvement lead: Victoria Thomas
Implementation lead: Denise Woods
Guidelines Development Group: The Guideline Development Group (GDG) oversees the development process.
Top


Email enquiries

If you have any queries please email nice@nice.org.uk
Top


 

Provisional schedule

Scoping workshop: 13 December 2007
Consultation on draft scope with stakeholders: 14 January 2008 - 11 February 2008
Consultation on draft guideline with stakeholders: 08 October - 05 November 2008
Pre-publication check: TBC
Publication date: May 2009
Top


 

Project history

Date Update
14 January 2008 The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed above, by the deadline shown.
14 February 2008 Consultation on the draft scope is complete and the scope is being modified in the light of comments received. When completed it will be posted on the website. It will define what aspects of care the guideline will cover and to whom it will apply.
11 June 2008 The Development Team may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4 weeks to respond. The Development Team will approach all registered stakeholders for this evidence. The Development Team may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the Development Team will accept relevant confidential data for consideration by the GDG.

Development of the clinical guideline is under way and is being led by the Short Clinical Guidelines Technical Team. The Guideline Development Group meets regularly to oversee and assist the identification, review and synthesis of the evidence, the incorporation of expert consensus opinion and the translation of the evidence into recommendations for practice and audit criteria. Please see timescales above for dates of consultation with stakeholders.
  The draft of the guideline is out for consultation with stakeholders. If you wish to comment, you need to do so via one of the registered stakeholder organisations by the deadline shown.
13 January 2009 Consultation on the draft of the guideline is complete and the guideline is being modified in the light of comments received. 
Top


 

Key documents

This page was last updated: 31 May 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.